Company: PMVP
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001140361-25-015610
Chunk: 25

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 25
---
aceutical companies, we believe that our board leadership structure has the requisite experience and expertise to oversee the board of directors’ risk oversight function. There is also open communication between management and directors through periodic reviews of our key risk areas and mitigation steps to reduce our risk exposure, and all directors are actively involved in the risk oversight function. Role of Independent Compensation Consultant The compensation committee has authority to appoint and retain a compensation consultant. The fees for services rendered by the compensation consultant are paid by our company. For executive compensation decisions for fiscal year 2024, our compensation committee engaged Pearl Meyer & Partners, LLC (“Pearl Meyer”), as its independent compensation consultant to advise on executive compensation matters including: overall compensation program design, peer group development and updates, and collecting market data to inform our compensation programs for our executives and members of our board of directors. We develop our compensation programs after reviewing publicly available compensation data and we also subscribe to other specialized life sciences and general industry surveys on an ongoing basis. Our compensation consultant advised the compensation committee on all of the principal aspects of executive compensation. Representatives from our compensation consultant attend meetings of the compensation committee when requested to do so. Our compensation consultant reports directly to our compensation committee and not to management, although it meets with management for purposes of gathering information for its analyses and recommendations. Our compensation committee has assessed the independence of our compensation consultant consistent with Nasdaq listing standards and has concluded that the engagement of our compensation consultant does not raise any conflict of interest. Stockholder Recommendations and Nominations to our Board of Directors Our nominating and corporate governance committee will consider recommendations and nominations for candidates to our board of directors from stockholders in the same manner as candidates recommended to the committee from other sources, so long as such recommendations and nominations comply with our amended and restated certificate of incorporation and amended and restated bylaws, all applicable company policies and all applicable laws, rules and regulations, including those promulgated by the SEC. Our nominating and corporate governance committee will evaluate such recommendations in accordance with its charter, our amended and restated bylaws and corporate governance guidelines and the director nominee criteria described above. A stockholder that wants to recommend a candidate to our board of directors should direct the recommendation in writing by letter to our corporate secretary at PMV Pharmaceuticals, Inc., 400 Alexander Park Drive, 14 TABLE OF CONTENTS Suite 301, Princeton, New Jersey 08540, Attention: Corporate Secretary. Such recommendation must include the candidate’s name, home and business contact information, detailed biographical data, relevant qualifications,